US Pharma MarketingBioMarin and n-Lorem partner on early research for ReNU syndrome therapy
BioMarin Pharmaceutical and n-Lorem Foundation have entered a collaboration and licence agreement to develop an investigational ASO therapy for ReNU syndrome.
BioMarin Pharmaceutical and n-Lorem Foundation have entered a collaboration and licence agreement to develop an investigational ASO therapy for ReNU syndrome.
Source: Pharmaceutical Technology